Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

Jongyoon Shinn; Juyeon Lee; Seon Ah Lee; Seon Ju Lee; Ah Hyun Choi; Jung Seo Kim; Su Jin Kim; Hyo Jin Kim; Cherin Lee; Yejin Kim; Joohyeon Kim; Jonghee Choi; Byungchae Jung; Taeho Kim; Hyeon Taek Nam; Hyungjun Kim; Yonghyun Lee

doi:10.3390/pharmaceutics14091969

Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

Jongyoon Shinn, Juyeon Lee, Seon Ah Lee, Seon Ju Lee, Ah Hyun Choi, Jung Seo Kim, Su Jin Kim, Hyo Jin Kim, Cherin Lee, Yejin Kim, Joohyeon Kim, Jonghee Choi, Byungchae Jung, Taeho Kim, Hyeon Taek Nam, Hyungjun Kim, Yonghyun Lee

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.

Original language	English
Article number	1969
Journal	Pharmaceutics
Volume	14
Issue number	9
DOIs	https://doi.org/10.3390/pharmaceutics14091969
State	Published - Sep 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

Keywords

Immunotherapy
gene delivery
inflammatory bowel disease
nanomedicines
oral drug delivery
siRNA

Access to Document

10.3390/pharmaceutics14091969

Cite this

@article{feb0f94058be47df9c4ed5b98c8746f0,

title = "Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease",

abstract = "RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.",

keywords = "Immunotherapy, gene delivery, inflammatory bowel disease, nanomedicines, oral drug delivery, siRNA",

author = "Jongyoon Shinn and Juyeon Lee and Lee, {Seon Ah} and Lee, {Seon Ju} and Choi, {Ah Hyun} and Kim, {Jung Seo} and Kim, {Su Jin} and Kim, {Hyo Jin} and Cherin Lee and Yejin Kim and Joohyeon Kim and Jonghee Choi and Byungchae Jung and Taeho Kim and Nam, {Hyeon Taek} and Hyungjun Kim and Yonghyun Lee",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/pharmaceutics14091969",

language = "English",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

TY - JOUR

T1 - Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

AU - Shinn, Jongyoon

AU - Lee, Juyeon

AU - Lee, Seon Ah

AU - Lee, Seon Ju

AU - Choi, Ah Hyun

AU - Kim, Jung Seo

AU - Kim, Su Jin

AU - Kim, Hyo Jin

AU - Lee, Cherin

AU - Kim, Yejin

AU - Kim, Joohyeon

AU - Choi, Jonghee

AU - Jung, Byungchae

AU - Kim, Taeho

AU - Nam, Hyeon Taek

AU - Kim, Hyungjun

AU - Lee, Yonghyun

PY - 2022/9

Y1 - 2022/9

N2 - RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.

AB - RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.

KW - Immunotherapy

KW - gene delivery

KW - inflammatory bowel disease

KW - nanomedicines

KW - oral drug delivery

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85138667317&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics14091969

DO - 10.3390/pharmaceutics14091969

M3 - Review article

AN - SCOPUS:85138667317

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 9

M1 - 1969

ER -

Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this